Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets

Maryam Etebari, Mohsen Navari, Claudio Agostinelli, Axel Visani, Cristiano Peron, Javeed Iqbal, Giorgio Inghirami, Pier Paolo Piccaluga

Research output: Contribution to journalArticle

Abstract

Lennert lymphoma (LL) is a lymphoepithelioid morphological variant of peripheral T-cell lymphoma—not otherwise specified (PTCL/NOS), clinically characterized by better prognosis if compared with other PTCL/NOS. Although well characterized as far as morphology and phenotype are concerned, very little is known regarding its molecular features. In this study, we investigated the transcriptional profile of this tumor aiming 1) to identify its cellular counterparts; 2) to better define its relation with other PTCLs—and, therefore, its possible position in lymphoma classification; and 3) to define pathogenetic mechanisms, possibly unveiling novel therapeutic targets. To address these issues, we performed gene and microRNA expression profiling on LL and other PTCL/NOS cases; we identified different genes and microRNAs that discriminated LL from other PTCL/NOS. Particularly, LL revealed a molecular signature significantly enriched in helper function and clearly distinguishable from other PTCL/NOS. Furthermore, PI3K/Akt/mTOR pathway emerged as novel potential therapeutic target. In conclusion, based on the already known particular morphological and clinical features, the new molecular findings support the hypothesis that LL might be classified as a separate entity. Preclinical and clinical studies testing the efficacy of PI3K/MTOR inhibitors in this setting are warranted.

Original languageEnglish (US)
Article number780
JournalFrontiers in Genetics
Volume10
DOIs
StatePublished - Sep 10 2019

Fingerprint

Lymphoma
Peripheral T-Cell Lymphoma
MicroRNAs
T-Lymphocytes
Phosphatidylinositol 3-Kinases
Gene Expression Profiling
Therapeutics
Phenotype
Genes
Neoplasms

Keywords

  • Lennert lymphoma
  • WHO classification
  • gene expression profiling
  • miRNA profiling
  • peripheral T-cell lymphoma—not otherwise specified

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Cite this

Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets. / Etebari, Maryam; Navari, Mohsen; Agostinelli, Claudio; Visani, Axel; Peron, Cristiano; Iqbal, Javeed; Inghirami, Giorgio; Piccaluga, Pier Paolo.

In: Frontiers in Genetics, Vol. 10, 780, 10.09.2019.

Research output: Contribution to journalArticle

Etebari, Maryam ; Navari, Mohsen ; Agostinelli, Claudio ; Visani, Axel ; Peron, Cristiano ; Iqbal, Javeed ; Inghirami, Giorgio ; Piccaluga, Pier Paolo. / Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets. In: Frontiers in Genetics. 2019 ; Vol. 10.
@article{c71fbef7456442d1a356692be1873ad7,
title = "Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets",
abstract = "Lennert lymphoma (LL) is a lymphoepithelioid morphological variant of peripheral T-cell lymphoma—not otherwise specified (PTCL/NOS), clinically characterized by better prognosis if compared with other PTCL/NOS. Although well characterized as far as morphology and phenotype are concerned, very little is known regarding its molecular features. In this study, we investigated the transcriptional profile of this tumor aiming 1) to identify its cellular counterparts; 2) to better define its relation with other PTCLs—and, therefore, its possible position in lymphoma classification; and 3) to define pathogenetic mechanisms, possibly unveiling novel therapeutic targets. To address these issues, we performed gene and microRNA expression profiling on LL and other PTCL/NOS cases; we identified different genes and microRNAs that discriminated LL from other PTCL/NOS. Particularly, LL revealed a molecular signature significantly enriched in helper function and clearly distinguishable from other PTCL/NOS. Furthermore, PI3K/Akt/mTOR pathway emerged as novel potential therapeutic target. In conclusion, based on the already known particular morphological and clinical features, the new molecular findings support the hypothesis that LL might be classified as a separate entity. Preclinical and clinical studies testing the efficacy of PI3K/MTOR inhibitors in this setting are warranted.",
keywords = "Lennert lymphoma, WHO classification, gene expression profiling, miRNA profiling, peripheral T-cell lymphoma—not otherwise specified",
author = "Maryam Etebari and Mohsen Navari and Claudio Agostinelli and Axel Visani and Cristiano Peron and Javeed Iqbal and Giorgio Inghirami and Piccaluga, {Pier Paolo}",
year = "2019",
month = "9",
day = "10",
doi = "10.3389/fgene.2019.00780",
language = "English (US)",
volume = "10",
journal = "Frontiers in Genetics",
issn = "1664-8021",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets

AU - Etebari, Maryam

AU - Navari, Mohsen

AU - Agostinelli, Claudio

AU - Visani, Axel

AU - Peron, Cristiano

AU - Iqbal, Javeed

AU - Inghirami, Giorgio

AU - Piccaluga, Pier Paolo

PY - 2019/9/10

Y1 - 2019/9/10

N2 - Lennert lymphoma (LL) is a lymphoepithelioid morphological variant of peripheral T-cell lymphoma—not otherwise specified (PTCL/NOS), clinically characterized by better prognosis if compared with other PTCL/NOS. Although well characterized as far as morphology and phenotype are concerned, very little is known regarding its molecular features. In this study, we investigated the transcriptional profile of this tumor aiming 1) to identify its cellular counterparts; 2) to better define its relation with other PTCLs—and, therefore, its possible position in lymphoma classification; and 3) to define pathogenetic mechanisms, possibly unveiling novel therapeutic targets. To address these issues, we performed gene and microRNA expression profiling on LL and other PTCL/NOS cases; we identified different genes and microRNAs that discriminated LL from other PTCL/NOS. Particularly, LL revealed a molecular signature significantly enriched in helper function and clearly distinguishable from other PTCL/NOS. Furthermore, PI3K/Akt/mTOR pathway emerged as novel potential therapeutic target. In conclusion, based on the already known particular morphological and clinical features, the new molecular findings support the hypothesis that LL might be classified as a separate entity. Preclinical and clinical studies testing the efficacy of PI3K/MTOR inhibitors in this setting are warranted.

AB - Lennert lymphoma (LL) is a lymphoepithelioid morphological variant of peripheral T-cell lymphoma—not otherwise specified (PTCL/NOS), clinically characterized by better prognosis if compared with other PTCL/NOS. Although well characterized as far as morphology and phenotype are concerned, very little is known regarding its molecular features. In this study, we investigated the transcriptional profile of this tumor aiming 1) to identify its cellular counterparts; 2) to better define its relation with other PTCLs—and, therefore, its possible position in lymphoma classification; and 3) to define pathogenetic mechanisms, possibly unveiling novel therapeutic targets. To address these issues, we performed gene and microRNA expression profiling on LL and other PTCL/NOS cases; we identified different genes and microRNAs that discriminated LL from other PTCL/NOS. Particularly, LL revealed a molecular signature significantly enriched in helper function and clearly distinguishable from other PTCL/NOS. Furthermore, PI3K/Akt/mTOR pathway emerged as novel potential therapeutic target. In conclusion, based on the already known particular morphological and clinical features, the new molecular findings support the hypothesis that LL might be classified as a separate entity. Preclinical and clinical studies testing the efficacy of PI3K/MTOR inhibitors in this setting are warranted.

KW - Lennert lymphoma

KW - WHO classification

KW - gene expression profiling

KW - miRNA profiling

KW - peripheral T-cell lymphoma—not otherwise specified

UR - http://www.scopus.com/inward/record.url?scp=85072822246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072822246&partnerID=8YFLogxK

U2 - 10.3389/fgene.2019.00780

DO - 10.3389/fgene.2019.00780

M3 - Article

C2 - 31552092

AN - SCOPUS:85072822246

VL - 10

JO - Frontiers in Genetics

JF - Frontiers in Genetics

SN - 1664-8021

M1 - 780

ER -